H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals to CHF 28 from CHF 24 and keeps a Buy rating on the shares after the FDA approved Agamree the treatment of Duchenne muscular dystrophy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue